Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 2Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Urinary Bladder Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 2Neoplasm Metastasis 2Recurrence Hepatocellular Carcinoma 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 43Nivolumab 24Gemcitabine 23Cyclophosphamide 21Paclitaxel 17Capecitabine 16fludarabine 14Ipilimumab 14aldesleukin 11Docetaxel 11130-nm albumin-bound paclitaxel 11Trastuzumab 10Cetuximab 10Bevacizumab 10Albumin-Bound Paclitaxel 9fludarabine phosphate 8Specimen Handling 8Interleukin-2 8Fluorouracil 8Cisplatin 8Biopsy 8Radiosurgery 7Oxaliplatin 7Irinotecan 7durvalumab 6avelumab 6Temozolomide 6Pemetrexed 6Leucovorin 6Carboplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm Metastasis × Mitomycin × Clear all
NCT02575859 2015-10-15

Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 1/2 Completed
20 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT00289445 2013-01-28

Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)

University Hospital Tuebingen

Phase 1/2 Completed
Gastrointestinal

Gastrointestinal Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡